← Leaderboards
Walter J Storkus
Roswell Park Cancer Institute Corp
$19,974,413
Attributed
$21,104,749
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,158,046 · 23
By mechanism
R01$13,887,648 · 9
P01$10,734,207 · 7
P50$2,533,157 · 6
M01$3,034 · 1
Top collaborators
- Jodi Kathleen Maranchie5 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Sharon S Evans$8,115,501
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaMalignant NeoplasmsDendritic CellsImmunotherapyBaseTumorClinical TrialsT-LymphocyteVaccinesPeptidesAntigensIn VivoImmuneExhibitsCd8b1 GeneResponseEpitopesCellsProgramsHla-A2 AntigenStagingImmunityAnimalsNeoplasm /Cancer Immunology
Grant awards (95)
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment$461,363
R01 · FY2025 · CA · contact PI
Developmental Research Program$128,736
P50 · FY2025 · CA · contact PI
Career Enhancement Program$125,385
P50 · FY2025 · CA · contact PI
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment$438,296
R01 · FY2024 · CA · contact PI
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs$225,566
P01 · FY2024 · CA · contact PI
Developmental Research Program$93,542
P50 · FY2024 · CA · contact PI
Career Enhancement Program$91,106
P50 · FY2024 · CA · contact PI
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment$452,135
R01 · FY2023 · CA · contact PI
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs$433,366
P01 · FY2023 · CA · contact PI
Developmental Research Program$90,620
P50 · FY2023 · CA · contact PI
Career Enhancement Program$88,259
P50 · FY2023 · CA · contact PI
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment$452,135
R01 · FY2022 · CA · contact PI
Developmental Research Program$77,965
P50 · FY2022 · CA · contact PI
Career Enhancement Program$75,427
P50 · FY2022 · CA · contact PI
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment$456,744
R01 · FY2021 · CA · contact PI
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs$441,751
P01 · FY2021 · CA · contact PI
Developmental Research Program$89,196
P50 · FY2021 · CA · contact PI
Career Enhancement Program$86,873
P50 · FY2021 · CA · contact PI
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs$460,426
P01 · FY2020 · CA · contact PI
Induction of Therapeutic Immunity in the Tumor Microenvironment$346,026
R01 · FY2020 · CA · contact PI
Induction of Therapeutic Immunity in the Tumor Microenvironment$335,873
R01 · FY2019 · CA · contact PI
Induction of Therapeutic Immunity in the Tumor Microenvironment$345,795
R01 · FY2018 · CA · contact PI
Induction of Therapeutic Immunity in the Tumor Microenvironment$343,580
R01 · FY2017 · CA · contact PI
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature$423,186
R01 · FY2016 · CA · contact PI
Induction of Therapeutic Immunity in the Tumor Microenvironment$341,699
R01 · FY2016 · CA · contact PI
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature$423,186
R01 · FY2015 · CA · contact PI
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature$410,490
R01 · FY2014 · CA · contact PI
Vaccines to promote Tc-1-based targeting of tumor stroma$287,547
R01 · FY2014 · CA · contact PI
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature$394,575
R01 · FY2013 · CA · contact PI
Vaccines to promote Tc-1-based targeting of tumor stroma$278,654
R01 · FY2013 · CA · contact PI
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature$419,449
R01 · FY2012 · CA · contact PI
Vaccines to promote Tc-1-based targeting of tumor stroma$296,440
R01 · FY2012 · CA · contact PI
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-Associate$195,261
P50 · FY2012 · CA · contact PI
Developmental Research Program$161,925
P50 · FY2012 · CA · contact PI
Vaccines to promote Tc-1-based targeting of tumor stroma$296,440
R01 · FY2011 · CA · contact PI
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-Associate$170,542
P50 · FY2011 · CA · contact PI
Developmental Research Program$140,308
P50 · FY2011 · CA · contact PI
Vaccines to promote Tc-1-based targeting of tumor stroma$305,608
R01 · FY2010 · CA · contact PI
Changes of CD4+ Lymphocyte Profile in Patients with Renal Cell Carcinoma and its$258,178
P01 · FY2010 · CA · contact PI
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-Associate$179,361
P50 · FY2010 · CA · contact PI
Developmental Research Program$146,454
P50 · FY2010 · CA · contact PI
Cytokine Gene Therapy of Cancer - Preclinical Studies$858,309
P01 · FY2009 · CA · contact PI
Combinational Immunotherapies Targeting Tumor RTKs$322,275
R01 · FY2009 · CA · contact PI
Changes of CD4+ Lymphocyte Profile in Patients with Renal Cell Carcinoma and its$252,531
P01 · FY2009 · CA · contact PI
IL-12 GENE THERAPY TO PRIME AND REPOLARIZE ANTI-TUMOR TH1-TYPE T CELLS$196,095
P01 · FY2009 · CA · contact PI
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-Associate$178,711
P50 · FY2009 · CA · contact PI
Developmental Research Program$145,517
P50 · FY2009 · CA · contact PI
ADMINISTRATIVE CORE$78,444
P01 · FY2009 · CA · contact PI
Cytokine Gene Therapy of Cancer - Preclinical Studies$925,900
P01 · FY2008 · CA · contact PI
Combinational Immunotherapies Targeting Tumor RTKs$312,885
R01 · FY2008 · CA · contact PI
Changes of CD4+ Lymphocyte Profile in Patients with Renal Cell Carcinoma and its$245,404
P01 · FY2008 · CA · contact PI
IL-12 GENE THERAPY TO PRIME AND REPOLARIZE ANTI-TUMOR TH1-TYPE T CELLS$211,539
P01 · FY2008 · CA · contact PI
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-Associate$177,763
P50 · FY2008 · CA · contact PI
Developmental Research Program$90,206
P50 · FY2008 · CA · contact PI
ADMINISTRATIVE CORE$84,625
P01 · FY2008 · CA · contact PI
Cytokine Gene Therapy of Cancer - Preclinical Studies$916,730
P01 · FY2007 · CA · contact PI
Combinational Immunotherapies Targeting Tumor RTKs$309,787
R01 · FY2007 · CA · contact PI
Dendritic Cell Strategies to Tumor Reactive T Cells$250,016
R01 · FY2007 · CA · contact PI
Changes of CD4+ Lymphocyte Profile in Patients with Renal Cell Carcinoma and its$243,813
P01 · FY2007 · CA · contact PI
IL-12 GENE THERAPY TO PRIME AND REPOLARIZE ANTI-TUMOR TH1-TYPE T CELLS$209,525
P01 · FY2007 · CA · contact PI
ADMINISTRATIVE CORE$82,679
P01 · FY2007 · CA · contact PI
Cytokine Gene Therapy of Cancer - Preclinical Studies$916,615
P01 · FY2006 · CA · contact PI
Combinational Immunotherapies Targeting Tumor RTKs$309,749
R01 · FY2006 · CA · contact PI
Dendritic Cell Strategies to Tumor Reactive T Cells$257,928
R01 · FY2006 · CA · contact PI
IL-12 GENE THERAPY TO PRIME AND REPOLARIZE ANTI-TUMOR TH1-TYPE T CELLS$214,454
P01 · FY2006 · CA · contact PI
Changes of CD4+ Lymphocyte Profile in Patients with Renal Cell Carcinoma and its$160,140
P01 · FY2006 · CA · contact PI
ADMINISTRATIVE CORE$85,793
P01 · FY2006 · CA · contact PI
Cytokine Gene Therapy of Cancer - Preclinical Studies$911,332
P01 · FY2005 · CA
Combinational Immunotherapies Targeting Tumor RTKs$320,091
R01 · FY2005 · CA
Dendritic Cell Strategies to Tumor Reactive T Cells$264,591
R01 · FY2005 · CA
Dendritic cell based therapies for murine tumors$237,966
R01 · FY2005 · CA
IL-12 GENE THERAPY TO PRIME AND REPOLARIZE ANTI-TUMOR TH1-TYPE T CELLS$208,206
P01 · FY2005 · CA
ADMINISTRATIVE CORE$83,295
P01 · FY2005 · CA
Dendritic Cell Strategies to Tumor Reactive T Cells$265,245
R01 · FY2004 · CA
Dendritic cell based therapies for murine tumors$238,090
R01 · FY2004 · CA
Dendritic Cell Strategies to Tumor Reactive T Cells$278,046
R01 · FY2003 · CA
IMMUNOBIOLOGY OF ATYPICAL NEVI$267,162
R01 · FY2003 · CA
Dendritic cell based therapies for murine tumors$238,832
R01 · FY2003 · CA
IMMUNOBIOLOGY OF ATYPICAL NEVI$259,524
R01 · FY2002 · CA
Dendritic cell based therapies for murine tumors$239,574
R01 · FY2002 · CA
CYTOKINE GENE THERAPY OF CANCER$460,085
P01 · FY2001 · CA
MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH$303,750
R01 · FY2001 · CA
IMMUNOBIOLOGY OF ATYPICAL NEVI$252,666
R01 · FY2001 · CA
Dendritic cell based therapies for murine tumors$240,192
R01 · FY2001 · CA
DENDRITIC CELL STRATEGY TO ELICIT TUMOR REACTIVE T CELLS$229,827
R01 · FY2001 · CA
IL-12--A HETERODIMERIC CYTOKINE FOR GENE THERAPY TO STIMULATE IMMUNITY$168,360
P01 · FY2001 · CA
CYTOKINE GENE THERAPY OF CANCER$1,044,326
P01 · FY2000 · CA
MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH$296,550
R01 · FY2000 · CA
IMMUNOBIOLOGY OF ATYPICAL NEVI$245,306
R01 · FY2000 · CA
DENDRITIC CELL STRATEGY TO ELICIT TUMOR REACTIVE T CELLS$223,446
R01 · FY2000 · CA
DENDRITIC CELL BASED THERAPIES FOR MURINE TUMORS$214,929
R01 · FY2000 · CA
IL-12--A HETERODIMERIC CYTOKINE FOR GENE THERAPY TO STIMULATE IMMUNITY$168,360
P01 · FY2000 · CA
IL-12--A HETERODIMERIC CYTOKINE FOR GENE THERAPY TO STIMULATE IMMUNITY$168,360
P01 · FY2000 · CA
CYTOKINE GENE THERAPY OF CANCER$20,000
P01 · FY2000 · CA
PHASE I STUDY OF MELAN-A/MART 1, GP100, AND TYROSINASE PEPTIDES WITH MF-59$3,034
M01 · FY2000 · RR